Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2022 16:55 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - - Butyrophilin heterodimeric fusion proteins from...
April 05, 2022 17:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins...
March 15, 2022 07:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

– Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer...
March 09, 2022 08:21 ET | Source: Shattuck Labs, Inc.

Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
March 02, 2022 08:39 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming March Conferences

AUSTIN, TX and DURHAM, NC, March 02, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
February 09, 2022 17:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference

AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion...
January 05, 2022 08:30 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Participation in Upcoming January Investor Conferences

AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as...
December 02, 2021 07:17 ET | Source: Shattuck Labs, Inc.

Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021

AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
November 09, 2021 08:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights

– Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials...
November 09, 2021 08:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252

– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients – – SL-172154 (SIRPα-Fc-CD40L)...